File: /home/govancoz/mail/new/1754428468.M47574P603244.zacp120.webway.host,S=10140,W=10321
Return-Path: <tomislav.andric@brodotrogir.hr>
Delivered-To: govancoz@zacp120.webway.host
Received: from zacp120.webway.host
by zacp120.webway.host with LMTP
id wJpYATR0kmhsNAkA8rC0kQ
(envelope-from <tomislav.andric@brodotrogir.hr>)
for <govancoz@zacp120.webway.host>; Tue, 05 Aug 2025 23:14:28 +0200
Return-path: <tomislav.andric@brodotrogir.hr>
Envelope-to: candice@govan.co.za
Delivery-date: Tue, 05 Aug 2025 23:14:28 +0200
Received: from kairos.brodotrogir.hr ([213.147.107.114]:62697 helo=bt-swes9.brodotrogir.local)
by zacp120.webway.host with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384
(Exim 4.98.2)
(envelope-from <tomislav.andric@brodotrogir.hr>)
id 1ujOzJ-00000002Wj2-1t0h
for candice@govan.co.za;
Tue, 05 Aug 2025 23:14:27 +0200
Received: from bt-swes9.brodotrogir.local (127.0.0.1) id hi9q2u0171sn for <candice@govan.co.za>; Tue, 5 Aug 2025 23:13:39 +0200 (envelope-from <tomislav.andric@brodotrogir.hr>)
Received: from mail.brodotrogir.hr ([10.10.200.131])
by bt-swes9.brodotrogir.local ([10.10.200.151]) (SonicWALL 9.0.6.2471 UNLICENSED )
with ESMTPS (version=TLSv1.2 cipher=ECDHE-RSA-AES256-SHA384 bits=256/256)
id o202508052113370041781-2; Tue, 05 Aug 2025 23:13:39 +0200
Received: from [192.168.59.13] (nsg-static-42.248.75.182-airtel.com [182.75.248.42]) by mail.brodotrogir.hr with SMTP;
Tue, 5 Aug 2025 23:13:27 +0200
Content-Type: multipart/alternative; boundary="===============0560763179=="
MIME-Version: 1.0
Subject: Proposal for Strategic Business Collaboration.
To: Recipients <tomislav.andric@brodotrogir.hr>
From: "Dr. Shingo Iwamoto" <tomislav.andric@brodotrogir.hr>
Date: Tue, 05 Aug 2025 14:13:10 -0700
Reply-To: drshingoiwamotopharm1@gmail.com
X-Src-Sender: (brodotrogir.hr) [10.10.200.131]:25
X-Mlf-Version: 9.0.6.2471
X-Mlf-License: B________
X-Mlf-UniqueId: o202508052113370041781
X-Spam-Status: No, score=3.3
X-Spam-Score: 33
X-Spam-Bar: +++
X-Ham-Report: Spam detection software, running on the system "zacp120.webway.host",
has NOT identified this incoming email as spam. The original
message has been attached to this so you can view it or label
similar future email. If you have any questions, see
root\@localhost for details.
Content preview: Dear Esteemed Professional, I hope this message finds you
well. Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer
based in Japan, is currently seeking a qualified individual to [...]
Content analysis details: (3.3 points, 5.0 required)
pts rule name description
---- ---------------------- --------------------------------------------------
1.2 RCVD_IN_BL_SPAMCOP_NET RBL: Received via a relay in bl.spamcop.net
[Blocked - see <https://www.spamcop.net/bl.shtml?182.75.248.42>]
0.0 URIBL_BLOCKED ADMINISTRATOR NOTICE: The query to URIBL was blocked.
See
http://wiki.apache.org/spamassassin/DnsBlocklists#dnsbl-block
for more information.
[URI: nichiiko.co.jp]
-0.0 SPF_PASS SPF: sender matches SPF record
0.0 KAM_DMARC_STATUS Test Rule for DKIM or SPF Failure with Strict
Alignment
0.0 RCVD_IN_VALIDITY_RPBL_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to
Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.147.107.114 listed in bl.score.senderscore.com]
0.0 RCVD_IN_VALIDITY_CERTIFIED_BLOCKED RBL: ADMINISTRATOR NOTICE: The
query to Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.147.107.114 listed in sa-trusted.bondedsender.org]
0.0 RCVD_IN_VALIDITY_SAFE_BLOCKED RBL: ADMINISTRATOR NOTICE: The query to
Validity was blocked. See
https://knowledge.validity.com/hc/en-us/articles/20961730681243
for more information.
[213.147.107.114 listed in sa-accredit.habeas.com]
0.2 FREEMAIL_REPLYTO_END_DIGIT Reply-To freemail username ends in digit
[drshingoiwamotopharm1(at)gmail.com]
0.0 HTML_MESSAGE BODY: HTML included in message
1.8 FREEMAIL_FORGED_REPLYTO Freemail in Reply-To, but not From
X-Spam-Flag: NO
This is a multi-part message in MIME format.
--===============0560763179==
MIME-Version: 1.0
Content-Type: text/plain;
charset="utf-8"
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
Dear Esteemed Professional,
I hope this message finds you well.
Nichi-Iko Pharmaceutical Co., Ltd., a leading pharmaceutical manufacturer =
based in Japan, is currently seeking a qualified individual to serve as our=
official representative in South Africa. This role involves managing miner=
al procurement and overseeing the establishment of our annex office in Sout=
h Africa under a five-year contractual agreement.
This is a strategic opportunity to represent a respected global brand and =
play a key role in expanding our international presence. We are offering a =
competitive compensation package along with decision-making autonomy.
If you are interested in learning more, kindly respond to this message for=
further details.
Warm regards,
Dr. Shingo Iwamoto
President & CEO
Nichi-Iko Pharmaceutical Co., Ltd.
5-4 Nihonbashi-Honcho 1-chome, Chuo-ku, Tokyo, Japan
Website: https://www.nichiiko.co.jp/
--===============0560763179==
MIME-Version: 1.0
Content-Type: text/html;
charset="utf-8"
Content-Transfer-Encoding: quoted-printable
Content-Description: Mail message body
<HTML><head><meta http-equiv=3D"Content-Type" content=3D"text/html; charset=
=3Diso-8859-1"/></head><BODY><P style=3D"FONT-SIZE: small; FONT-FAMILY: Ari=
al, Helvetica, sans-serif; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRA=
NSFORM: none; FONT-WEIGHT: 400; COLOR: rgb(34,34,34); FONT-STYLE: normal; O=
RPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255=
,255); TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps:=
normal; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial=
; text-decoration-style: initial; text-decoration-color: initial">Dear Este=
emed Professional,</P>
<P style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; WH=
ITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 40=
0; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-=
SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font=
-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-=
width: 0px; text-decoration-thickness: initial; text-decoration-style: init=
ial; text-decoration-color: initial">I hope this message finds you well.</P=
>
<P style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; WH=
ITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 40=
0; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-=
SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font=
-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-=
width: 0px; text-decoration-thickness: initial; text-decoration-style: init=
ial; text-decoration-color: initial">Nichi-Iko Pharmaceutical Co., Ltd., a =
leading pharmaceutical manufacturer based in Japan, is currently seeking a =
qualified individual to serve as our official representative in South Afric=
a. This role involves managing mineral procurement and overseeing the estab=
lishment of our annex office in South Africa under a five-year contractual =
agreement.</P>
<P style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; WH=
ITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 40=
0; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-=
SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font=
-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-=
width: 0px; text-decoration-thickness: initial; text-decoration-style: init=
ial; text-decoration-color: initial">This is a strategic opportunity to rep=
resent a respected global brand and play a key role in expanding our intern=
ational presence. We are offering a competitive compensation package along =
with decision-making autonomy.</P>
<P style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; WH=
ITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 40=
0; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-=
SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font=
-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-=
width: 0px; text-decoration-thickness: initial; text-decoration-style: init=
ial; text-decoration-color: initial">If you are interested in learning more=
, kindly respond to this message for further details.</P>
<P style=3D"FONT-SIZE: small; FONT-FAMILY: Arial, Helvetica, sans-serif; WH=
ITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: 40=
0; COLOR: rgb(34,34,34); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; LETTER-=
SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font=
-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-=
width: 0px; text-decoration-thickness: initial; text-decoration-style: init=
ial; text-decoration-color: initial">Warm regards,<BR>Dr. Shingo Iwamoto<BR=
>President & CEO<BR>Nichi-Iko Pharmaceutical Co., Ltd.<BR>5-4 Nihonbash=
i-Honcho 1-chome, Chuo-ku, Tokyo, Japan<BR>Website: <A style=3D"COLOR:=
rgb(17,85,204)" rel=3D"noreferrer noreferrer">https://www.nichiiko.<WBR>co=
.jp/</A></P></BODY></HTML>
<br /><br />
--===============0560763179==--